Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Aminopyrine and Barbital Injection is a fixed-dose combination pharmaceutical product used for its antipyretic and analgesic properties. It is primarily indicated for the treatment of acute fever and various pain conditions, including headache, neuralgia, and muscle pain. The formulation contains two active ingredients: aminopyrine, a pyrazolone derivative that acts as a non-steroidal anti-inflammatory drug (NSAID) by inhibiting cyclooxygenase enzymes to reduce prostaglandin synthesis, and barbital, a long-acting barbiturate that acts as a sedative and enhances the analgesic effect by modulating GABA-A receptors. Although sometimes categorized alongside traditional products in older Chinese pharmaceutical contexts, it is a conventional chemical medication. It is manufactured by Guangxi Nanning Baihui Pharmaceutical and is typically administered via intramuscular injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Aminopyrine and Barbital Injection.